Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cyclo Therapeutics, Inc. CYTH NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
46/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$0.95
+31.8%

Cyclo Therapeutics, Inc. (CYTH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.72. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is CYTH = $1 (+31.8% upside).

Financials: revenue is $1M, +13.5%/yr average growth. Net income is $20M (loss), growing at -32.8%/yr. Net profit margin is -1863.4% (negative). Gross margin is 90.9% (-1.8 pp trend).

Balance sheet: total debt is $1M against $5M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 1.45 (adequate). Debt-to-assets is 7.8%. Total assets: $13M.

Analyst outlook: 1 / 3 analysts rate CYTH as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 46/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$0.95
▲ 31.83% Upside
Average Price Target
The 12-month price target for Cyclo Therapeutics, Inc. is $0.95.

CYTH SharesGrow Score Overview

54/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CYTH

✓
VALUE Pass
90/100
CYTH trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $1, implying +38.8% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
CYTH: +13.5%/yr revenue is, -32.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet CYTH: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 1.45 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
CYTH: Gross margin is 90.9% (-1.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 1 / 3 analysts rate CYTH as buy (33%). Analyst consensus target is $1 (+38.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CYTH: Net profit margin is -1863.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.55-1.6199
Volume186.81K
Avg Volume (30D)1.76M
Market Cap$23.59M
Beta (1Y)-0.57
Share Statistics
EPS (TTM)-1.23
Shares Outstanding$16.33M
IPO Date2000-05-03
Employees8
CEON. Scott Fine
Financial Highlights & Ratios
Revenue (TTM)$1.08M
Gross Profit$977.95K
EBITDA$-20.03M
Net Income$-20.06M
Operating Income$-20.05M
Total Cash$9.25M
Total Debt$1.03M
Net Debt$-8.21M
Total Assets$13.25M
Price / Earnings (P/E)-0.6
Price / Sales (P/S)21.92
Analyst Forecast
1Y Price Target$0.95
Target High$0.95
Target Low$0.95
Upside+31.8%
Rating ConsensusHold
Analysts Covering3
Buy 33% Hold 67% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS23254X2018

Price Chart

Track all markets on TradingView
CYTH
Cyclo Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
0.55 52WK RANGE 1.62

People Also View

ITCI
ITCI
Intra-Cellular Therapies, Inc.
$131.87
+0.00%
 AMRX
AMRX
Amneal Pharmaceuticals, Inc.
$13.12
+2.26%
 PAHC
PAHC
Phibro Animal Health Corporation
$59.02
-0.94%
 IRWD
IRWD
Ironwood Pharmaceuticals, Inc.
$4.04
+10.68%
 AQST
AQST
Aquestive Therapeutics, Inc.
$4.15
-0.95%
 LFCR
LFCR
Lifecore Biomedical, Inc.
$5.20
+5.26%
 TKNO
TKNO
Alpha Teknova, Inc.
$3.03
+0.33%
 ASRT
ASRT
Assertio Holdings, Inc.
$18.02
+0.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message